Literature DB >> 32304255

Commentary on Larance et al. (2020): Priorities and concerns of people who use opioids are key to scaling up XR-buprenorphine.

Chelsea L Shover1.   

Abstract

Entities:  

Keywords:  Buprenorphine; long-acting medication; opioid agonist treatment; opioid use disorder; opioids; prescribing guidelines

Mesh：

Substances：

Year:  2020        PMID： 32304255      PMCID： PMC8050841          DOI： 10.1111/add.15048

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  4 in total

1.  Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Barbara R Haight; Susan M Learned; Celine M Laffont; Paul J Fudala; Yue Zhao; Amanda S Garofalo; Mark K Greenwald; Vijay R Nadipelli; Walter Ling; Christian Heidbreder
Journal:  Lancet       Date:  2019-02-18       Impact factor: 79.321

2.  Predictors of availability of long-acting medication for opioid use disorder.

Authors:  Chelsea L Shover; Keith Humphreys
Journal:  Drug Alcohol Depend       Date:  2019-09-25       Impact factor: 4.492

3.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.

Authors:  Jake R Morgan; Bruce R Schackman; Jared A Leff; Benjamin P Linas; Alexander Y Walley
Journal:  J Subst Abuse Treat       Date:  2017-07-03

4.  Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.

Authors:  Briony Larance; Louisa Degenhardt; Jason Grebely; Suzanne Nielsen; Raimondo Bruno; Paul Dietze; Kari Lancaster; Sarah Larney; Thomas Santo; Marian Shanahan; Sonja Memedovic; Robert Ali; Michael Farrell
Journal:  Addiction       Date:  2020-02-05       Impact factor: 6.526
  4 in total
  1 in total

1.  Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

Authors:  Jake R Morgan; Alexander Y Walley; Sean M Murphy; Avik Chatterjee; Scott E Hadland; Joshua Barocas; Benjamin P Linas; Sabrina A Assoumou
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.